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SIGNIFICANCE
The Danish clinical database DERMBIO collects routine 
information during the treatment of psoriasis with biolo­
gics or small molecules. These include physicians’ evalua­
tion of severity, with the Psoriasis Area Severity Index, 
and the influence on patients’ lives, with the Dermatology 
Life Quality Index. Among 1,677 patients the correlation 
between Psoriasis Area Severity Index and Dermatology 
Life Quality Index was weak­to­moderate during a 5­year 
treatment period. The changes in Psoriasis Area Severity 
Index correlated weak­to­moderately with changes in Der­
matology Life Quality Index during the first 12 months of 
treatment, with the strongest correlation seen during the 
first 3 months. Symptoms were the most important fac­
tor in the Dermatology Life Quality Index. Measuring and 
monitoring of patients’ symptoms are important, and ad­
ditional measures to capture symptoms might be beneficial 
in daily practice.
The initiation and evaluation of treatment with biolo-
gics for psoriasis is based on the Psoriasis Area Seve-
rity Index (PASI) and/or Dermatological Life Quality 
Index (DLQI). However, these indices do not always 
correlate well, and changes in the DLQI do not always 
follow changes in the PASI. Based on data from the Da-
nish national registry (DERMBIO), this study investi-
gated the correlation between changes in PASI and 
DLQI in a cohort of patients with moderate-to-severe 
psoriasis treated with biologics or apremilast using 
Spearman’s rank correlation analyses. The correlation 
analysis of 1,677 patients, of whom 276 had available 
data after 5 years, showed weak-to-moderate correla-
tion between PASI and DLQI during a 5-year period and 
between changes in PASI and DLQI: 0.58 (p < 0.0001) 
for baseline to 3 months and 0.42 (p < 0.0001) for 3 
to 12 months. The first question on “Symptoms and 
feelings” made up the largest proportion of the overall 
DLQI. The correlation between PASI and DLQI is weak-
to-moderate and varies over time. Changes in PASI 
correlate weak-to-moderately with changes in DLQI 
during the first 12 months of treatment, with symp-
toms being the most important factor contributing to 
impaired quality of life.
Key words: psoriasis; patient­reported outcomes; Psoriasis 
Area and Severity Index; Dermatology Life Quality Index; bio­
logics.
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Psoriasis is a common chronic immune-mediated in-flammatory skin disease, which confers an increased 
psychosocial burden (1) and impaired quality of life 
(2), often in a disease-severity dependent manner (3). 
Short-term assessment of treatment efficacy is mostly 
based on physician evaluation, whereby a 75% reduc-
tion in the Psoriasis Area and Severity Index (PASI75) 
remains the current treatment goal in most guidelines for 
patients with moderate-to-severe psoriasis (4–7). How-
ever, some patients are not satisfied with this reduction, 
and a 90% improvement (PASI90) has been suggested 
as a clinically important endpoint, and a treatment goal 
(8–10). Indeed, patients achieving PASI90 report lower 
Dermatology Life Quality Index (DLQI) than patients 
achieving PASI75–89 (11) and patients with clear skin 
based on Physicians Global Assessment (PGA) report 
lower DLQI compared with those with almost clear 
skin (12). However, in smaller studies, changes in PASI 
during the first 3 months of treatment do not correlate 
fully with changes in DLQI (13, 14) and reported cor-
relations between PASI and DLQI range from negligible 
(13, 15) to strong (16, 17). This apparent dissociation 
between PASI and DLQI is not yet fully elucidated, 
but pruritus has been shown to affect this relationship 
(18). We therefore investigated the relationship between 
changes in PASI and DLQI in a nationwide cohort of all 
Danish patients with psoriasis treated with biologics or 
novel small molecule therapies. 
MATERIALS AND METHODS
Data sources
The study was approved by the Danish Data Protection Agency 
(ref. HGH-2016-048, I-Suite: 04520). In Denmark, approval 
of an ethics committee is not required for register studies. The 
study was carried out in accordance with the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) 
recommendations (19).
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The DERMBIO registry (20–28) is a Danish nationwide registry 
wherein all treatment series with biologics, biosimilars, and novel 
small-molecule agents for psoriasis are registered. Registration and 
prospective data collection in DERMBIO have been mandatory 
since 2007. Data are reported from all academic hospital centres 
(85% of all treatments) with an estimated coverage of 100% of 
the treatment series and a small proportion of patients are seen in 
clinical practices, with an estimated coverage of 88% of treatment 
series (27). To maximize data integrity only patients treated in 
hospital clinics were included (28).
Patient selection
Patients treated for at least 30 days with available data on PASI 
and DLQI at baseline and at a minimum of one subsequent visit 
were included. The patients were only included the first time they 
met the inclusion criteria, i.e. at the time of their first treatment 
in DERMBIO. 
Statistical analysis
For continuous data, means with standard deviations (SD) and 
medians with range were reported, and for categorical outcomes 
numbers with percentages were presented. The correlation bet-
ween changes in PASI and DLQI were assessed for the periods: 
baseline to 3 months, 3 to 12 months, and baseline to 12 months. 
The correlations were evaluated based on absolute changes in 
PASI and DLQI relative changes in both PASI and DLQI, and 
for relative change in PASI and absolute change in DLQI, as all 
outcomes have been used in prior studies (13, 14, 29). We then 
investigated the correlation between changes in PASI and changes 
in the newly proposed DLQI-R (30). Correlation analyses were 
performed between PASI and DLQI at baseline, after 3, 6 and 
12 months of treatment, and then for each subsequent year until 
5 years of treatment. In addition, correlation analyses were per-
formed between PASI and DLQI-R at the same time-points (30). 
Patients were stratified based on PASI (PASI < 5 and PASI ≥ 5; 
PASI < 10 and PASI ≥ 10) to assess the importance of different 
disease severities on impact on quality of life. Patient-reported 
outcomes were assessed for different response categories: PASI 
< 50, PASI50–< 75, PASI75–< 90, PASI90–< 100, and PASI100. 
For patients for whom the single questions in the DLQI were avail-
able, descriptive analysis for the percentage each question contri-
buted to the overall DLQI, the correlation between PASI and each 
question, and correlation between changes in PASI and the single 
questions were assessed. Correlation coefficients were assessed 
using Spearman’s rank correlation (rs). Correlation coefficients are 
considered negligible if rs = 0.0–< 0.30, weak if rs = 0.30–<0.50, 
moderate if rs = 0.50–< 0.70, strong if rs = 0.70–<0.90, and very 
strong if rs = 0.90–1.00 (31). Fischer’s z transformation was used to 
compute 95% confidence intervals (CI) and z scores were used to 
test for statistical differences. Wilcoxon rank-sum test was used for 
comparison of continuous data. All analyses were performed using 
SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA). 
Dermatology Life Quality Index 
The DLQI consists of 10 individual questions, which are scored 
from 0 to 3, resulting in a total score of 0–30 (32). In question 
3–10 it is possible to answer the question “Not relevant”, which 
is then scored 0. The DLQI can be divided into 6 domains, which 
each consist of 1 or 2 questions (32).
Psoriasis Area and Severity Index
In PASI, the body is divided in 4 regions, which are evaluated on 
erythema, induration, and scaling multiplied by the area affected 
of the body part, resulting in a total score of 0–72 (33).
RESULTS
The study population consisted of 1,677 unique patients, 
with a strong predominance of male patients (65%) and 
bio-naïve patients (76.7%, Table I). After 3 months of 
treatment 1,308 patients had available data, 1,090 after 
6 months, 1,069 after 12 months, 744 after 24 months, 
553 after 36 months, 382 after 48 months, and 276 after 
5 years of treatment. 
Correlation between changes in disease severity and 
changes in quality of life over time 
Correlation analysis between changes in PASI and DLQI 
during the first year of treatment yielded Spearman’s 
rhos in the range 0.34–0.58 (Table II). The highest 
correlation was observed for relative changes in PASI 
and DLQI from baseline to 3 months. Significantly 
stronger correlations were seen for the period: baseline 
to 3 months compared with 3–12 months (p = 0.0001). 
There were no differences between the correlation 
coefficients obtained with DLQI-R (data available on 
Table I. Baseline characteristics of included patients (n = 1,677)
Baseline characteristics
Age, years, mean ± SD 44.9 ± 14.3
Sex, n (%)
  Male 1,090 (65)
  Female 587 (35)
Psoriatic arthritis, n (%) 559 (33.3)
Plaque psoriasis, n (%) 1,591 (94.9)
Weight, kg, mean ± SD 90.6 ± 22.6
Body mass index, kg/m2, mean ± SD 29.1 ± 6.4
Duration, years, mean ± SD 21.4 ± 12.4
Psoriasis Area Severity Index, mean ± SD 10.7 ± 6.9
Dermatology Life Quality Index, mean ± SD 11.6 ± 7.4
Biologic naive, n (%) 1,286 (76.7)
Treated with, n (%)
  Adalimumab 621 (37.0)
  Etanercept 217 (12.9)
  Infliximab 107 (6.4)
  Ustekinumab 572 (34.1)
  Secukinumab 137 (8.2)
  Ixekizumab 19 (1.1)
  Brodalumab 1 (0.1)
  Apremilast 3 (0.2)
SD: standard deviation.
Table II. Spearman’s rho (rs) for changes in Psoriasis Area Severity 
Index (PASI) and Dermatology Life Quality Index (DLQI) after 
treatment with biologics
Period rs 95% CI p­value
Absolute change in PASI and DLQI
  Baseline–3 months 0.50 0.46–0.54 < 0.0001
  3–12 months 0.40 0.34–0.45 < 0.0001
  Baseline–12 months 0.45 0.40–0.50 < 0.0001
Relative change in PASI and DLQI
  Baseline–3 months 0.58 0.54–0.61 < 0.0001
  3–12 months 0.42 0.34–0.49 < 0.0001
  Baseline–12 months 0.51 0.46–0.55 < 0.0001
Relative change in PASI and absolute change in DLQI
  Baseline–3 months 0.43 0.39–0.48 < 0.0001
  3–12 months 0.34 0.26–0.40 < 0.0001
  Baseline–12 months 0.35 0.30–0.41 < 0.0001
CI: confidence interval. p-values < 0.05 are in bold.
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request). Patients were stratified on their biological 
exposure, where patients with a previous biological 
treatment showed significantly higher correlation co-
efficients for all periods for absolute changes in both 
PASI and DLQI (Table SI1). For the biologic-exposed 
patients, those with 2 or more prior treatments showed 
significantly higher correlation coefficients for baseline 
to 3 months in absolute changes in both PASI and DLQI 
than those with only one prior treatment (Table SII1). 
No differences were seen for patients with psoriatic 
arthritis compared with those without psoriatic arthritis 
(data available on request). Likewise, no difference was 
seen when patients with other forms of psoriasis were 
excluded (data available on request). 
Correlation between disease severity and quality of life 
A weak correlation was observed at baseline (rs = 0.33), 
and after 3 and 6 months of treatment the correlation 
between PASI and DLQI was moderate (Fig. 1). At the 
subsequent time-points a decrease in correlation bet-
ween PASI and DLQI was observed, and after 5 years 
of treatment, based on 276 observations, the correlation 
between PASI and DLQI was similar to that observed 
at baseline (rs = 0.35). The same correlations were seen 
for DLQI-R (data available on request). 
In 11,450 visits a PASI < 5 was reported and in 2,586 
visits a PASI ≥ 5; no difference between correlation coef-
ficients was observed between these 2 groups (PASI < 5, 
rs = 0,41; PASI ≥ 5, rs = 0.38). When visits were divided 
into PASI<10 (n = 12836) vs. PASI ≥ 10 (n = 1,190) a 
substantial difference in correlations was observed: a 
negligible correlation (rs = 0.13) between PASI and DLQI 
for patients with PASI ≥ 10 and a weak-to-moderate cor-
relation (rs = 0.47) for patients with PASI < 10. In addi-
tion, a steady increment of mean DLQI with increasing 
PASI until PASI ≥ 15 was observed; hereafter an increase 
in disease severity was followed by a small or no increase 
in impact on quality of life (Fig. 2). 
Stratified based on response criteria
Statistically significant lower DLQIs were observed 
for patients with a higher delta PASI after 3, 6 and 12 
months and statistically significant larger reduction in 
DLQIs, except for PASI90–< 100 vs. PASI100, where 
no difference between changes in DLQI was observed 
(Table III). 
Distribution and percentage of each question at different 
time-points
In total, for 1,045 patients the single questions in the 
DLQI were available at baseline, for 878 they were 
available after 3 months, for 712 after 6 months, for 699 
after 12 months, for 503 after 24 months, for 381 after 
36 months, for 252 after 48 months, and 184 patients 
had available single questions of the DLQI after 5 years 
of treatment. At baseline the first 2 questions in DLQI 
concerning the “Symptoms and feelings” domain made 
up 36% (23% + 13%) of the overall DLQI and the rest 
of the questions each made up between 5% and 13% of 
the overall DLQI (Fig. 3). After 5 years of treatment 
the “Symptoms and feelings” domain made up 69% 
(58% + 11%) of the overall DLQI (Fig. 3). The distri-
bution of answers to each question showed that 94% of 
patients reported ≥1 in question 1 at baseline and 60% 
of the patients did so after 5 years of treatment, and 
10–26% of the patients reported ≥1 for the rest of the 
questions after 5 years (Fig. 4). Approximately 10% of 
the patients answered “Not relevant” in the questions 
6, 7 and 9 (Fig. 4). 
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Fig. 1. Correlation between Psoriasis Area Severity Index (PASI) 
and Dermatology Life Quality Index (DLQI) during treatment 
with biologics or apremilast assessed at baseline (month 0, number 
of patients with available data, n = 1,677), month 3 (n = 1,308), month 6 
(n = 1,090), month 12 (n = 1,069), month 24 (n = 744), month 36 (n = 553), 
month 48 (n = 382), and month 60 (n = 276). Correlation coefficients (rs) 
were assessed using Spearman’s rho, and confidence intervals (CI) were 
computed with Fisher’s z transformation.
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3331
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Fig. 2. Mean Dermatology Life Quality Index (DLQI) for patients 
with a Psoriasis Area Severity Index (PASI) of 0–<5 (n = 11,450), 
PASI 5–<10 (n = 1,386), PASI10–PASI<15 (n = 730), PASI15–<20 (n = 278), 
PASI20–<25 (n = 103), PASI25–<30 (n = 44), and PASI≥30 (n = 35).The 
red dotted line represents the linear increment in DLQI for PASI groups 
from PASI0–<15. The grey dotted line represents the linear increment in 
DLQI for PASI groups from PASI≥15.
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Correlation between PASI and each question in 
Dermatology Life Quality Index at different time-points.
The correlation between PASI and each of the individual 
questions in the DLQI was assessed for the same time-
points. The first question on “Symptoms and feelings” 
was weak-to-moderately correlated with PASI and cor-
relation coefficients above 0.30 were observed at all 
time-points (Table SIII1). Question 4 on “Daily activities” 
and question 10 on “Treatment” showed weak correla-
tions (rs = 0.24–0.39) with PASI. The second question 
of “Symptoms and feelings” regarding embarrassment 
was weakly correlated with PASI during the first year of 
treatment. The rest of the individual questions showed 
negligible correlations with PASI during the 5-year 
treatment period (Table SIII1). For correlation between 
changes in PASI and changes in the individual question 
in DLQI, the highest correlation was observed between 
changes in PASI and changes in the first question of 
“Symptoms and feelings” (Table SIV1). 
DISCUSSION
In this study of 1,677 Danish patients receiving biolo-
gics or apremilast for psoriasis, weak-to-moderate cor-
relations coefficients were found between changes in 
PASI and DLQI during the first 12 months of treatment 
Table III. Psoriasis Area Severity Index (PASI) and Dermatology Life Quality Index (DLQI) for patients divided into 5 groups based on 
response after 3, 6 and 12 months
PASI<50 PASI50–<75 PASI75–<90 PASI90–<100 PASI100
3 months 
Number of patients 272 270 259 168 339
PASI, mean ± SD 7.41 ± 5.32 4.22 ± 2.42 2.20 ± 1.20 0.77 ± 0.47 0 
DLQI, mean ± SD 6.76 ± 6.32  5.07 ± 5.33 3.68 ± 4.54 2.10 ± 3.75 1.14 ± 2.49
  Median (min;max) 5 (0; 29) 3 (0;25) 2 (0;30) 1 (0;26) 0 (0;16)
p = 0.0018a p = 0.0009b p <0.0001c p <0.0001d
DLQI0–1, n (%)* 61 (23.92) 82 (32.06) 106 (43.62) 100 (64.51) 250 (78.37)
ΔDLQI, mean±SD 3.20 ± 5.90 7.30 ± 6.00 9.03 ± 6.74 11.99 ± 7.00 11.60 ± 7.33
  Median (min;max) 2 (–19; 25) 6.5 (–10;26) 8(–5;29) 12 (–8;29) 11 (–7;30)
p <0.0001a p = 0.0070b p <0.0001c p = 0.47d
6 months
Number of patients 199 171 217 178 325
PASI, mean ± SD 7.26 ± 5.55 3.88 ± 2.33 2.22 ± 1.05 0.87 ± 0.56 0
DLQI, mean ± SD 6.86 ± 6.46 4.49 ± 4.72 3.23 ± 3.87 2.07 ± 3.39 1.09 ± 2.39
  Median (min;max) 5 (0;27) 3 (0;27) 2 (0;19) 1 (0;25) 0 (0;13)
p = 0.0022a p =0.0040b p <0.0001c p <0.0001d
DLQI0–1, n (%)* 46 (26.59) 56 (34.78) 89 (44.28) 101 (63.52) 242 (80.40)
ΔDLQI, mean±SD 2.11 ± 6.52 7.02 ± 6.86 9.46 ± 6.29 11.64 ± 7.18 11.86 ± 7.40
  Median (min;max) 0 (–23;22) 6 (–5;28) 9 (–4;28) 11 (0;30) 12 (–5;30)
p <0.0001a p = 0.0003b p = 0.011c p = 0.61d
12 months
Number of patients 156 161 228 173 351
PASI, mean±SD 6.77 ± 6.54 3.75 ± 2.18 2.09 ± 1.18 0.78 ± 0.50 0 
DLQI, mean±SD 5.47 ± 5.58 3.44 ± 4.08 3.29 ± 4.27 2.43 ± 3.96 1.01 ± 2.61
  Median (min;max) 3.5 (0;26) 2 (0;22) 2 (0;26) 1 (0;27) 0 (0;21)
p = 0.0027a p = 0.44b p = 0.0020c p < 0.0001d
DLQI0–1, n (%)* 49 (34.03) 55 (35.95) 107 (48.41) 105 (62.88) 283 (83.48)
ΔDLQI, mean±SD 3.17 ± 6.12 7.33 ± 6.38 9.40 ± 6.93 11.38 ± 6.71 11.65 ± 7.42
  Median (min;max) 3 (–13;18) 6 (–7;26) 9 (–7;30) 11 (–10;28) 11 (–11;30)
p < 0.0001a p = 0.0035b p = 0.0059c p = 0.87d
PASI50 vs. PASI50–< 75a; PASI50–< 75 vs. PASI75–< 90b; PASI75–<90 vs. PASI90–<100c; PASI90–<100 vs. PASI100d.
*Percentage calculated based on available DLQI at the time-point.
SD: standard deviation. p-values < 0.05 are in bold.
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Fig. 3. The percentage that each of the individual questions of the Dermatology Life Quality Index (DLQI) contributes to the overall DLQI 
(a) at baseline (number of patients with available individual question of DLQI, n = 1,045), (b) after 3 months of treatment (n = 878), (c) after 12 months 
of treatment (n = 699), and (d) after 60 months of treatment (n = 184).
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and between PASI and DLQI during a 5-year treatment 
period. The first question on “Symptoms and feelings” 
demonstrated the strongest correlation with PASI, and 
changes in PASI for the individual questions of DLQI, 
and contributed most to the overall DLQI.
Previous studies have demonstrated weak correlations 
between relative changes in PASI and DLQI from base-
line to weeks 10–16 (13, 14), moderate correlation for 
percentage changes in both PASI and DLQI (29) and in 
a systematic review of randomized clinical trials (RCT) 
a strong correlation was demonstrated between mean 
percentage reduction in PASI and mean reduction in 
DLQI (34). In the same review patients achieving PASI75 
showed clinically meaningful higher reductions in mean 
DLQI compared with those achieving PASI50–75 and 
PASI < 50 (34) and in RCTs, patients achieving PASI90 
reported lower DLQI than those achieving PASI75–89 
(11), and a higher proportion of patients achieving 
PASI100 report a DLQI of 0 or 1 compared with patients 
achieving PASI75–< 100 (35).
In the current study, correlations between changes in 
PASI and DLQI were highly dependent on how these 
changes were assessed; relative changes in both PASI and 
DLQI yielded the highest correlation coefficient, and re-
lative changes in PASI and absolute changes in DLQI the 
lowest. The correlations were similar to those reported in 
previous studies (13, 14, 29). Patients achieving higher 
PASI response had lower mean DLQI and higher reduc-
tions in absolute DLQI. In contrast to previous reporting 
(34), the difference between each group was not conside-
red clinically meaningful (< 3.2) (36), probably because 
patients had lower PASI and DLQI compared with those 
seen in clinical trials. Nevertheless, as in previous studies 
(35), patients with higher clearance were more likely to 
report a DLQI of 0 or 1. This emphasizes the positive 
effects and importance of skin clearance on patients’ 
quality of life. Similar distributions were observed after 
3, 6 and 12 months. Interestingly, we observed a lower 
correlation for the 3–12-month period compared with 
the baseline to 3 months period. Although speculative, 
this may indicate that patients early in the treatment are 
more satisfied with relative improvements compared with 
later in their treatment course, and that patients might 
change their perception upon treatment success. This 
notion is supported by correlations between PASI and 
DLQI during treatment, which varied throughout the 
5-year period and that an absolute low PASI was asso-
ciated with a low DLQI. Introducing the recent proposed 
DLQI-R (30) did not alter the correlations between PASI 
and DLQI. Interestingly, once a certain disease severity 
was reached an additional worsening was not reflected 
in quality of life. This might indicate that DLQI is not 
comprehensive to describe impact on quality of life for 
patients with severe psoriasis, and possibly underesti-
mates disease severity in these patients (37). The use 
of DLQI-R might overcome this problem; however, we 
observed similar results for DLQI-R in this study (data 
available on request). 
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Fig. 4. Distribution of answers for each of the individual questions of the Dermatology Life Quality Index (DLQI) (a) at baseline (number 
of patients with available individual question of DLQI, n = 1,045), (b) after 3 months of treatment (n = 878), (c) after 12 months of treatment (n = 699), 
and (d) after 60 months of treatment (n = 184). NR corresponds to the answer “Not relevant”, a score of 0 corresponds to the answer “Not at all” or 
“Question unanswered”, a score of 1 corresponds to the answer “a little”, a score of 2 corresponds to the answer “a lot”, and a score of 3 corresponds to 
the answer “very much”.
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The relatively low correlation at some time-point 
illustrates that DLQI might ensure other relevant infor-
mation about perceived disease severity and treatment 
advantages than PASI alone. However, the contribution 
of the individual questions in DLQI was skewed, and 
for some questions more than half of the patients scored 
0. This indicates some questions in the DLQI to be of 
little or no relevance to a lot of patients, whereas symp-
toms are important for most patients. In addition to the 
DLQI, a symptom scoring index, i.e. Psoriasis Symptom 
Inventory (38), could add to the patient’s perspective 
and might be beneficial in the daily clinic. Moreover, 
patients with healthy skin might also report high DLQI, 
i.e. wearing a wool sweater might itch and impact on 
choice of clothes; thus factors other than psoriasis can 
add to the overall DLQI. 
Certain limitations should be considered when inter-
preting the present findings. Although the overall data 
capture was good, some patients had missing data at dif-
ferent time-points. While these data were considered to 
be missing completely at random, we cannot refute that 
patients with a high DLQI were more likely to be registe-
red in the DERMBIO registry, which would have biased 
towards the null, i.e. no correlation. An important limita-
tion is the fact that our study comprised a highly selected 
population of patients treated either with biologics or 
apremilast, which may differ from patients treated with, 
for example, conventional systemics. However, only 3 
patients received apremilast, and the results might not 
apply for this treatment. Strengths of the study include 
the well-characterized nature of our population, the high 
number of patients, prospective data collection, the use 
of widely established measures, i.e. PASI and DLQI, and 
the high external validity owing to the routinely collected 
data from daily clinical practice. 
In conclusion, this study found that the correlation 
between PASI and DLQI is weak-to-moderate and varies 
over time, where changes in PASI correlate weak-to-
moderately with changes in DLQI during the first 12 
months. The DLQI might not capture the full patient 
disease perspective, and additional measures to capture 
subjective symptoms might be beneficial in future studies 
and daily practice.
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